ARS Pharmaceuticals (SPRY) Return on Capital Employed (2021 - 2026)

ARS Pharmaceuticals (SPRY) has 6 years of Return on Capital Employed data on file, last reported at 78.46% in Q1 2026.

• For the quarter ending Q1 2026, Return on Capital Employed fell 6977.0% year-over-year to 78.46%; the trailing twelve-month figure through Mar 2026 stood at 78.46% (down 6977.0% YoY), and the FY2025 full-year result was 59.76%, down 5862.0% from the prior year.
• Return on Capital Employed declined to 78.46% in Q1 2026, from 57.69% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 9.53% in Q3 2022 to a low of 78.46% in Q1 2026.
• A 5-year average of 22.73% and a median of 24.08% in 2023 frame the typical range for Return on Capital Employed.
• Across the five-year window, Return on Capital Employed soared 3252 bps in 2022 and plunged 6977 bps in 2026, its largest moves.
• Tracing SPRY's Return on Capital Employed over 5 years: stood at 13.11% in 2022, then sank by 116 bps to 28.31% in 2023, then surged by 96 bps to 1.18% in 2024, then plunged by 4782 bps to 57.69% in 2025, then plunged by 36 bps to 78.46% in 2026.
• Business Quant data shows SPRY's Return on Capital Employed at 78.46% in Q1 2026, 57.69% in Q4 2025, and 31.06% in Q3 2025.